1. Home
  2. RVSN vs APRE Comparison

RVSN vs APRE Comparison

Compare RVSN & APRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Rail Vision Ltd.

RVSN

Rail Vision Ltd.

N/A

Current Price

$4.38

Market Cap

10.9M

Sector

N/A

ML Signal

N/A

Logo Aprea Therapeutics Inc.

APRE

Aprea Therapeutics Inc.

HOLD

Current Price

$0.78

Market Cap

11.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RVSN
APRE
Founded
2016
2006
Country
Israel
United States
Employees
47
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
10.9M
11.5M
IPO Year
N/A
2019

Fundamental Metrics

Financial Performance
Metric
RVSN
APRE
Price
$4.38
$0.78
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$4.10
AVG Volume (30 Days)
28.6K
121.7K
Earning Date
03-31-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
21.22
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$860.32
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.17
$0.55
52 Week High
$9.39
$2.22

Technical Indicators

Market Signals
Indicator
RVSN
APRE
Relative Strength Index (RSI) 31.21 45.70
Support Level $4.20 $0.75
Resistance Level $5.21 $0.81
Average True Range (ATR) 0.33 0.07
MACD 0.07 -0.01
Stochastic Oscillator 24.75 37.67

Price Performance

Historical Comparison
RVSN
APRE

About RVSN Rail Vision Ltd.

Rail Vision Ltd is an early commercialization stage technology company focused on railway safety systems using AI-integrated sensing systems. The company develops and commercializes proprietary, multi-spectral electro-optic platforms that provide extended-range situational awareness and real-time hazard detection. Using machine learning algorithms to identify and classify obstacles, the company's technology enhances safety, improves operational efficiency, and supports continuity across deployments.

About APRE Aprea Therapeutics Inc.

Aprea Therapeutics Inc is a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers. It develops small molecule inhibitors designed to exploit genetic mutations in cancer to widen the therapeutic window and is intended to make treatments more effective at destroying cancer cells while sparing healthy tissue. The company's pipeline of clinical and preclinical programs includes APR-1051, a WEE1 inhibitor; ATRN-119 (Mosipasertib), an oral small molecule inhibitor of ataxia telangiectasia and Rad3-related, or ATR; and an early-stage program, APR-1602. These candidates are being developed for broad applications in cancer treatment.

Share on Social Networks: